Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.68 |
| ▸ | OGG1 | O15527 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.65 |
| ▸ | NPC1 | O15118 | 6/20 | 0.65 |
| ▸ | RAB9A | P51151 | 6/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 12/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | G6PD | P11413 | 1/20 | 0.60 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9423020 | 0.86 | HDAC1 (0.61) | HDAC1HDAC8HDAC6OGG1SMN1; SMN2 | |
| SCHEMBL7984062 | 0.83 | HDAC1 (0.79) | HDAC1HDAC8HDAC6OGG1SMN1; SMN2 | |
| SCHEMBL1886020 | 0.81 | HDAC1 (1.00) | HDAC1HDAC8HDAC6OGG1SMN1; SMN2 | |
| SCHEMBL6477287 | 0.80 | OGG1 (1.00) | HDAC1HDAC8HDAC6OGG1SMN1; SMN2 | |
| SCHEMBL4386528 | 0.80 | LMNA (0.69) | HDAC1HDAC8HDAC6OGG1SMN1; SMN2 | |
| SCHEMBL13659606 | 0.80 | MCL1 (0.65) | HDAC1HDAC8HDAC6OGG1SMN1; SMN2 | |
| SCHEMBL14609078 | 0.79 | NPC1 (0.64) | HDAC1HDAC8HDAC6OGG1SMN1; SMN2 | |
| SCHEMBL5162422 | 0.78 | OGG1 (0.64) | HDAC1HDAC8HDAC6OGG1SMN1; SMN2 | |
| SCHEMBL11951263 | 0.77 | TLR3 (0.76) | HDAC1HDAC8HDAC6OGG1SMN1; SMN2 | |
| SCHEMBL11951514 | 0.77 | TLR3 (0.76) | HDAC1HDAC8HDAC6OGG1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962244-B2 | Compounds for modulating RNA binding proteins and uses therefor | UNIVERSITY OF MASSACHUSETTS (US) | 2015-02-24 | — | — | US | disclosed |
| US-20130217685-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-22 | — | — | US | disclosed |
| US-8377639-B2 | Compounds for modulating RNA binding proteins and uses therefor | UNIVERSITY OF MASSACHUSETTS (US) | 2013-02-19 | — | — | US | disclosed |
| US-20110065704-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217685-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | TIA1, ZFP3, RBM3 | HDAC1 446/4885HDAC8 851/4885HDAC6 637/4885 |
| US-20110065704-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | TIA1, ZFP3, RBM3 | HDAC1 446/4885HDAC8 851/4885HDAC6 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.